HemaSphere (Jun 2022)

S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG

  • M. Lübbert,
  • P. Wijermans,
  • M. Kicinski,
  • S. Chantepie,
  • W. van der Velden,
  • R. Noppeney,
  • L. Griskevicius,
  • A. Neubauer,
  • M. Crysandt,
  • R. Vrhovac,
  • M. Luppi,
  • S. Fuhrmann,
  • E. Audisio,
  • A. Candoni,
  • O. Legrand,
  • R. Foà,
  • G. Gaidano,
  • D. van Lammeren-Venema,
  • E. F. Posthuma,
  • M. Hoogendoorn,
  • A. Giraut,
  • M. Stevens-Kroef,
  • J. H. Jansen,
  • E. Ammatuna,
  • J.-P. Vilque,
  • R. Wäsch,
  • H. Becker,
  • N. Blijlevens,
  • U. Dührsen,
  • F. Baron,
  • S. Suciu,
  • S. Amadori,
  • A. Venditti,
  • G. Huls

DOI
https://doi.org/10.1097/01.HS9.0000843392.61672.18
Journal volume & issue
Vol. 6
pp. 26 – 27

Abstract

Read online

No abstracts available.